Drug Trial Radar · NCT07594509
Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery
Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
May 31, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beijing Anzhen Hospital; The Affiliated Hospital of Qingdao University; Changzhou First People's Hospital; The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Bengbu Medical University; West China Hospital; Shanghai East Hospital
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of perioperative vericiguat in patients undergoing cardiovascular surgery. Patients at high risk of heart failure or with confirmed cardiac dysfunction will be randomly assigned to receive either vericiguat plus standard of care or standard of care alone. The primary objective is to determine whether perioperative administration of vericiguat can reduce (I) the Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury; (II) Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI), and the incidence of Major Adverse Cardiovascular Events (MACE) within 12 months after surgery.
Conditions
- Cardio Vascular Disease
- Cardiopulmonary Bypass
Interventions
VericiguatDrug
Patients will receive oral vericiguat in addition to standardized perioperative care. Vericiguat will be initiated 3 days before surgery at a dose of 2.5 mg once daily. Postoperatively, upon resumption of enteral nutrition, vericiguat will be continued and gradually up-titrated every 2 weeks based on blood pressure tolerability to 5 mg, and then to a target dose of 10 mg once daily, taken with food, for a total duration of 1 months.
Standard of Care GroupDrug
Patients will receive standardized perioperative cardiovascular surgery care alone, without vericiguat or placebo. Standard care includes preoperative preparation, postoperative monitoring, anti-infection, antiplatelet/anticoagulation, diuretics, beta-blockers, SGLT2 inhibitors, and other symptomatic treatments for heart failure according to current guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial InjuryTime frame: Up to 7 days postoperatively (or until ICU discharge, whichever comes first).
- Incidence of Major Adverse Cardiovascular Events (MACE)Time frame: Up to 6 months postoperatively
- Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI)Time frame: Up to 7 days postoperatively.
- Maximum Sequential Organ Failure Assessment (SOFA) ScoreTime frame: Up to 7 days postoperatively.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.